Poly-oxygenated Metal Hydroxide Resuscitative Fluid for Hemorrhagic Shock
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current resuscitative fluids fail to provide oxygen to hypoxic cells and tissues following major blood loss, limiting their effectiveness in treating severe blood loss and hemorrhagic shock, and existing oxygen therapeutics have limitations such as hypertension and leukocyte activation concerns.
Innovation Solution
A poly-oxygenated metal hydroxide, specifically aluminum hydroxide (Ox66™), is used as a colloid or crystalline solution to release oxygen gas molecules, which can be intravenously administered as a blood additive, providing oxygenation to interstitial tissues and being agnostic to blood type, with particle sizes optimized for minimal toxicity and maximal efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If HBOCs are used as oxygen therapeutics, then oxygen delivery to tissues is improved, but hypertension occurs due to systemic arteriolar constriction
Solution Approach 1:
The patent changes the chemical parameters of oxygen carriers by using poly-oxygenated metal hydroxides with multiple oxygen atoms per molecule (e.g., Al(OH)3 with 6 oxygen atoms). This fundamental parameter change allows oxygen delivery without the vasoconstrictive effects of HBOCs, resolving the contradiction between oxygen delivery and hypertension.
Solution Approach 2:
The patent employs composite material structures where metal hydroxides form clathrate compounds with oxygen molecules trapped within their lattice structures. This composite approach enables oxygen storage and delivery while avoiding the harmful physiological effects associated with traditional HBOCs.
2Quantity of substance
If PFCs are used as oxygen therapeutics, then oxygen delivery to tissues is improved, but leukocyte activation occurs
Solution Approach 1:
The patent fundamentally changes the chemical nature of oxygen carriers from perfluorocarbons to poly-oxygenated metal hydroxides. This parameter change eliminates the leukocyte activation issue while maintaining oxygen delivery capability, as the metal hydroxide structure does not trigger the same immune response as PFCs.
3Quantity of substance
If blood transfusion is performed to replace lost blood volume, then oxygen delivery is improved, but blood typing and disease transmission risks remain
Solution Approach 1:
The patent introduces poly-oxygenated metal hydroxides as an intermediary oxygen carrier that does not involve blood products. This intermediary substance provides oxygen delivery without the risks of blood typing compatibility or blood-borne disease transmission, effectively mediating between oxygen supply and safety requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution significantly increases tissue oxygenation, extends product life, and allows immediate administration without blood typing, providing effective resuscitation in emergency situations, including military and civilian trauma cases, with demonstrated survival benefits in preclinical studies.
Implementation Method 1
a poly-oxygenated metal hydroxide comprising a clathrate compound containing free O2 gas molecules in a fluid, configured as a colloid or a crystalline solution
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
A colloid or crystalline solution with the addition of a poly-oxygenated metal hydroxide comprising a clathrate compound having free O2 gas molecules. The oxygen enabled solution is configured to oxygenate the interstitial tissue of a mammal, such as a mammal having depleted PISF O2 suffering from severe blood loss and/or experiencing hemorrhagic shock. The solution can be intravenously administered. In some embodiments, the poly-oxygenated metal hydroxide is an aluminum poly-oxygenated hydroxide. The poly-oxygenated metal hydroxide may have particles having a diameter of less than or equal to 1 um, and specifically having a diameter of less than or equal to 100 nm.